Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of Enavogliflozin and Metformin in Healthy Men
NCT04064073Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Cmax of DWP16001, AUClast of DWP16001 and 2 more. Started Aug 2019; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04064073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064073.